Soolantra is a prescription cream for adults with inflammatory rosacea. Its ivermectin-based formula helps calm inflammation and reduce Demodex mite density in affected skin.
Soolantra is a prescription topical cream containing ivermectin as its active pharmaceutical ingredient. The dose is stated on the pack — follow the leaflet. It belongs to the topical antiparasitic and anti-inflammatory treatments used in dermatology.
Soolantra is a dermatological cream built around a single active substance: ivermectin. The dose is stated on the pack — follow the leaflet. It comes in a 45 g tube, intended for once-daily facial application according to the leaflet. The cream is manufactured by Galderma, a company with a long track record in medical dermatology.
Ivermectin itself is not new to medicine. It has been used orally for decades to treat parasitic infections [1]. What Soolantra does differently is deliver it directly into the skin at a low, steady concentration, aimed specifically at the inflammatory component of rosacea rather than at a systemic parasite.
The cream vehicle matters more than it might seem. Facial skin affected by rosacea is often reactive, easily irritated by alcohol-based or heavily fragranced products. Soolantra's base is formulated to spread thinly and absorb without leaving a greasy residue, which matters for patient adherence — nobody sticks with a daily treatment that feels unpleasant under makeup or sunscreen.
One detail patients often miss: the tube's narrow nozzle is designed to dispense a controlled amount. Squeezing too hard gives you more product than the pea-sized dose actually needed for the whole face.
Soolantra is applied once daily, in the evening or morning, as part of a fixed routine rather than an as-needed treatment.
| Parameter | Detail | Note |
|---|---|---|
| Frequency | Once daily | Same time each day improves adherence |
| Amount per use | Pea-sized | Enough for the full face |
| Areas covered | Forehead, nose, chin, both cheeks | Not spot-treatment |
If a dose is missed, apply it as soon as remembered that same day. Doubling up the next day to compensate does not speed up results and raises the chance of local irritation.
A mistake seen often in practice: patients apply the cream only to visible red spots instead of the whole face. Rosacea involves a field of skin, not isolated lesions, so spot-treating leaves untreated Demodex mites and inflammatory signaling active in the surrounding tissue.
Ivermectin in Soolantra works through two separate but connected pathways. First, it has a direct anti-inflammatory effect, dampening the activity of pro-inflammatory cytokines that drive the redness, papules, and pustules typical of rosacea. Second, it has antiparasitic activity against Demodex folliculorum, a skin mite present in higher densities on rosacea-affected skin than on healthy skin [2].
Researchers have not settled on a single cause of rosacea. Current understanding treats it as the product of innate immune dysregulation, vascular changes, and a disproportionate Demodex load, acting together rather than in isolation. Soolantra does not chase one of these mechanisms alone. By calming inflammatory signaling while reducing mite density, it addresses two of the three recognized contributors at once.
Soolantra is indicated for the treatment of inflammatory lesions associated with rosacea in adult patients.
This dual action sets it apart from antibiotic-based rosacea treatments, which work almost exclusively through anti-inflammatory and antimicrobial routes without addressing Demodex. A 2025 review in the Journal of Clinical and Aesthetic Dermatology noted that ivermectin's mite-reducing action may explain its durability of response compared with antibiotic creams, where relapse after stopping treatment is common [3].
Known hypersensitivity to ivermectin or any excipient in the formulation.
It should not be applied to open wounds, severely sunburned skin, or areas with active eczema flares, since broken skin barriers absorb more active ingredient than intact skin and raise the risk of systemic exposure.
Soolantra has not been studied for safety during pregnancy and breastfeeding in large controlled trials, and MOHAP guidance for topical ivermectin products recommends medical consultation before use in these situations.
This medication is not for you if you have a known allergy to ivermectin or another ingredient in the cream. Ask a physician before using it during pregnancy or breastfeeding, and do not apply it to open wounds, severe sunburn, or active eczema.
Clinical trial data submitted to regulatory bodies show that Soolantra is generally well tolerated, with most adverse events being mild and localized to the application site [4].
These effects tend to appear in the first one to two weeks and often fade as the skin adjusts. Hypersensitivity reactions, including contact dermatitis, occur rarely but warrant stopping treatment and seeking medical advice if swelling, blistering, or significant worsening develops.
One nuance that's easy to overlook: a temporary increase in redness during the first weeks does not automatically mean the treatment is failing. In clinical practice, this initial flush is sometimes mistaken for a worsening of rosacea itself, when it is actually a short-lived reaction to the active ingredient settling into the skin.
Dermatologists who prescribe Soolantra regularly describe a fairly consistent pattern: slow but steady improvement rather than a dramatic early response. Patients who expect overnight clearing are often disappointed in week one and need reassurance to stay consistent through the full 12-week evaluation window typically used in clinical practice.
Honestly, the biggest predictor of success isn't the cream itself — it's whether the patient keeps applying it daily without skipping. Physicians often note that inconsistent use is the single most common reason for a perceived lack of response, more so than any issue with the drug's pharmacology.
Gentle, fragrance-free moisturizers and mineral sunscreens are generally compatible with Soolantra. Active ingredients such as retinoids, exfoliating acids, or benzoyl peroxide can increase irritation when combined with ivermectin cream and should be introduced only under medical supervision. The EMA's 2015 product information for topical ivermectin notes that concurrent use of multiple irritant topical agents raises the likelihood of localized adverse skin reactions. Spacing out different active products to different times of day can reduce this risk.
Soolantra is specifically indicated for the inflammatory lesions of rosacea — the papules and pustules — rather than for persistent facial redness or visible blood vessels. Patients whose main concern is erythema or telangiectasia often need a different treatment approach alongside or instead of ivermectin cream. A 2025 review in the Journal of Clinical and Aesthetic Dermatology distinguishes between lesion-targeted and redness-targeted rosacea therapies for this reason. A dermatologist can clarify which component of rosacea is dominant in a given case before starting treatment.
Applying more than once daily or using more than a pea-sized amount does not accelerate results and increases the likelihood of burning, dryness, and irritation. The 2015 EMA product information confirms that once-daily use reflects the dosing studied in clinical trials submitted to regulatory review. Overuse can also deplete the tube faster without any added benefit.
Soolantra does not treat persistent erythema and telangiectasia as effectively as it treats inflammatory papules and pustules because these features are driven by different vascular mechanisms. The WHO's 2021 dermatology guidance separates rosacea subtypes by dominant clinical feature precisely because treatments differ by mechanism. Patients with mixed presentations sometimes need combination therapy to address both lesion types and background redness.
The 2014 FDA prescribing information describes clinical studies that followed patients for 12 months of continuous use without a documented loss of effectiveness or new safety signals beyond the known local skin reactions. Many dermatologists continue treatment well beyond the initial 12-week evaluation period if the response is favorable and tolerability remains good. Periodic reassessment with a physician helps determine whether continued use, dose adjustment, or a treatment pause is appropriate.
This medication is not for you if you have a known hypersensitivity to ivermectin or any component of the cream, active skin infections in the treatment area, or significant skin barrier damage such as open wounds or severe sunburn. The EMA's 2015 product information also advises medical guidance during pregnancy and breastfeeding, since robust safety data in these groups is limited. Anyone uncertain about a skin diagnosis should get it confirmed by a physician before starting, since several rosacea mimics respond poorly to ivermectin cream.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
The first two weeks were rough, my skin felt tight and a bit itchy. By week six the redness on my cheeks had calmed down noticeably. Still get occasional flare-ups if I eat something spicy, but the change is a big improvement.
Honestly expected faster results. It took almost a month before I saw a real difference, but my dermatologist said that was normal. The bumps on my nose and chin are mostly gone now.
Didn't love the burning sensation when I first started. It went away after about ten days. My skin looks calmer, less patchy red than before, but I still need to be careful with sun exposure.
Used it consistently every night. Took longer than I expected, around five weeks for visible change, but now my face looks far less inflamed. One tube lasted close to two months for me.
Mixed feelings. It helped with the pustules but did nothing for the general redness and visible vessels I have. My dermatologist said that part needs a different approach, which I didn't realize going in.
